The effects of nitric oxide (NO) and noradrenergic activation in the posterior hypothalamus on arterial pressure tolerance induced by subcutaneous injection of nitroglycerin (NTG) was investigated in anesthetized Sprague-Dawley rats. Intravenous injections of NTG (3, 10, and 30 µg/kg) and sodium nitroprusside (1, 3, and 10 µg/kg) produced dose-dependant decreases in arterial blood pressure. Tolerance to NTG was produced by subcutaneous administration of 4.0 mg of NTG as 4 separate hourly injections of 1.0 mg each, affecting the dose-dependent response of NTG IV injection. The 4 high-dose NTG pulse injections produced a marked shift in the dose—response curves for arterial pressure depression induced by intravenous injection of the challenge doses of NTG, but did not alter hypotensive responses to sodium nitroprusside. The tolerance responses to arterial pressure depression were enhanced by a bilateral microinjection of NTG (1 nmol) and by diethylamine NONOate (1 nmol), an NO donor, into the posterior hypothalamus. Bilateral microinjection of guanethidine (1.5 nmol), a noradrenergic blocker, into the posterior hypothalamus inhibits NTG tolerance in a period of time within 2 hours. We conclude that exogenous NO and noradrenergic activation in the posterior hypothalamus play an important role in arterial pressure tolerance to systemically administered NTG.
Needleman P., Corr PB, Johnson EMDrugs used for the treatment of angina: organic nitrates, calcium channel blockers, and β-adrenergic antagonists. In: Gilman AG, Goodman LS, Rall TWMurad F, eds. The Pharmacological Basis of Therapeutics. New York: Macmillan;1985:806-826.
2.
Brien JF, McLaughlin BE, Kobus SM, Kawamoto JH, Nakatsu K., Marks GSMechanism of glyceryl trinitrate-induced vasodilation. Relationship between drug biotransformation, tissue cyclic GMP elevation and relaxation of rabbit aorta. J Pharmacol Exp Ther. 1987;244:322-327.
3.
Napoli C., Ignarro LJNitric oxide-releasing drugs. Annu Rev Pharmacol Toxicol. 2003;43:97-123.
4.
Erhardt L.Nitrate tolerance. State of the art-Chairman's summary. Acta Pharmacol Toxicol. 1986;59(suppl VI): 129-132.
5.
Parker JONitrate tolerance. A problem during continuous nitrate administration. Eur J Clin Pharmacol. 1990; 38(suppl 1):S21-S25.
6.
Silber S.Nitrates: why and how should they be used? Current status of the clinical usefulness of nitroglycerin, isosorbide dinitrate and isosorbide-5-mononitrate . Eur J Clin Pharmacol. 1990;38(suppl 1):S35-S51.
7.
Rinde-Hoffman D., Glasser SP, Arnett DKUpdate on nitrate therapy. J Clin Pharmacol. 1991;31:697-701.
8.
Axelsson KL, Ahlner J., Ljusegren METolerance to organic nitroesters in experimental animals. An assessment of in vitro and in vivo investigations. Acta Pharmacol Toxicol . 1986;59(suppl VI):121-128.
9.
Kistler JP, Lees RS, Candia G.Intravenous nitroglycerin in experimental cerebral vasospasm: a preliminary report. Stroke. 1979;10:26-29.
10.
Frazee JG, Giannotta SL, Stern WEIntravenous nitroglycerin for the treatment of chronic cerebral vasoconstriction in the primate. J Neurosurg. 1981;55:865-868.
11.
Kaverina NVThe mechanism of nitroglycerin action on the cardiac vessels. Biull Eksp Biol Med. 1960 ;49:75-78.
12.
Kaverina NV , Vysotskaya NB, Rosonov Yu B., Shugina TMConnection between central action of glyceryl trinitrate and monoamine metabolism of the brain. Biull Eksp Biol Med. 1967;64:1310-1313.
13.
Ma SX, Long JPCentral noradrenergic activity is responsible for nitroglycerin-induced cardiovascular effects in the nucleus tractus solitarii. Brain Res. 1991;559:297-303.
14.
Ma. SX, Long JPCentral noradrenergic activity and the cardiovascular effects of nitroglycerin and amyl nitrite. J Cardiovasc Pharmacol. 1992;20:826-836.
15.
Ma SX, Long JP, Bhatnagar RKFurther studies on central actions of nitroglycerin and lack of evidence for nitroglycerin interacting on [3H]clonidine binding sites in cortex membranes . J Pharmacol Exp Ther. 1992;261: 1187-1194.
16.
Ma SX, Schmid PG, Long JPNoradrenergic mechanisms and the cardiovascular actions of nitroglycerin. Life Sci. 1994;55:1595-1603.
17.
Bousquet P., Schwartz J.Alpha-adrenergic drugs: pharmacological tools for the study of the central vasomotor control. Biochem Pharmacol. 1983 ;32:1459-1965.
18.
Antonaccio MJCentral transmitters: physiology, pharmacology, and effects on the circulation . In: Antonaccio MJ, ed. Cardiovascular Pharmacology. 2nd ed. New York: Raven Press; 1984:155-195.
19.
Nakata T., Berard W., Kogosov E., Alexander N.Microdialysis in the posterior hypothalamus: sodium chloride affects norepinephrine release, mean arterial pressure, heart rate and behavior in awake rats. Brain Res Bull. 1990;2:593-598.
20.
Shonis CA, Waldrop TGAugmented neuronal activity in the hypothalamus of spontaneously hypertensive rats. Brain Res Bull. 1993;30:45-51.
21.
Ma SX, Ignarro LJ, Byrns R., Li XYIncreased nitric oxide concentrations in posterior hypothalamus and central sympathetic function on nitrate tolerance following subcutaneous nitroglycerin . Nitric Oxide. 1999;3:153-161.
22.
Ma SX, Pandjaitan M., Ojije G.Enhanced nitric oxide release/synthesis in the posterior hypothalamus during nitroglycerin tolerance in rats. Eur J Pharmacol. 2003; 47:179-187.
23.
Rush ML, Lang WJ, Rand MJStudies on compensatory reflexes and tolerance to glyceryl trinitrate (GTN) . Eur J Pharmacol. 1971;16:148-155.
24.
Needleman PJ , Johnson EMMechanism of tolerance development to organic nitrates. J Pharmacol Exp Ther. 1973;184:709-715.
25.
Parker JO, Parker JDNeurohormonal activation during nitrate therapy: a possible mechanism for tolerance. Am J Cardiol. 1992;70:93B-97B.
26.
Boesgard S. , Aldershvile J., Poulsen HE, Loft S., Anderson ME, Meister A.Nitrate tolerance in vivo is not associated with depletion of arterial or venous thiol levels. Circ Res . 1994;74:115-120.
27.
Imhof PR, Rennwald D., Muller P., Howald H., Burkart F.Circulatory counter-regulations induced by continuous administration of nitroglycerin . Methods Find Exp Clin Pharmacol. 1989;11:409-414.
28.
Dupuis J., Lalonde G., Lemieux R., Rouleau JLTolerance to intravenous nitroglycerin in patients with congestive heart failure: role of increased intravascular volume, neurohormonal activation and lack of prevention with N-acetylcysteine. J Am Coll Cardiol. 1990;19:923-931.
29.
Muiesan ML, Boni E., Cefis M., et al. Efficacy of transdermal nitroglycerin in combination with an ACE-inhibitor in patients with chronic stable angina pectoris. J Am Coll Cardiol. 1991;2(suppl A):377A.
30.
Katz RJ, Levy WS, Buff L., Wasserman AGPrevention of nitrate tolerance with angiotensin converting enzyme inhibitors . Circulation. 1991;83:1271-1277.
31.
Chang CC, Costa E., Brodie BBInteraction of quanethidine with adrenergic neurons. J Pharmacol Exp Ther. 1965; 147:303-312.
32.
Woosley RL, Nies ASGuanethidine. N Engl J Med. 1976;295:1053-1057.
33.
Joyce PI, Rizzi D., Calo G., Rowbotham DJ, Lambert DGThe effects of guanethidine and local anesthetics on the electrically stimulated mouse vas deferens. Anesth Analg. 2002;95:1335-1343.
34.
Kurz MA, Boyer TD, Whalen R., Peterson TE, Harrison DGNitroglycerin metabolism in vascular tissue: role of glutathione S-transferases and relationship between NO and NO2-formation. Biochem J. 1993;292:545-550.
35.
Routledge MN , Wink DA, Keefer LK, Dipple A.DNA sequence changes induced by two nitric oxide donor drugs in the supF assay. Chem Res Toxicol. 1994;7:628-632.
36.
Torfgard K. , Ahnler J., Axelsson KL, Norlander B., Bertler A.Tissue distribution of glyceryl trinitrate and the effect on cGMP levels in rat. Pharmacol Toxicol. 1989;64: 369-372.
37.
Torfgard K. , Ahnler J.Tissue levels of glyceryl trinitrate and cGMP after in vivo administration in rat, and the effect of tolerance development . Can J Physiol Pharmacol. 1991; 69:1257-1261.
38.
Kumer SC, Vrana KEIntricate regulation of tyrosine hydroxalase activity and gene expression . J Neurochem. 1996;67:443-462.
39.
Bevilaqua LR , Graham ME, Dunkley PR, von Nagy-Felsobuki EI, Dickson PWPhosphorylation of Ser19 alters the conformation of tyrosine hydroxylase to increase the rate of phosphorylation of Ser40. J Biol Chem. 2001;276: 40411-40416.
40.
Sandner P., Kornfeld M., Ruan X., Arendshorst WJ, Kurtz A.Nitric oxide/cAMP interactions in the control of rat renal vascular resistance . Circ Res. 1999;84:186-192.
41.
Troadec JD, Marien M., Mourlevat S., et al. Activation of the mitogen-activated protein kinase (ERK1/2) signaling pathway by cyclic AMP potentiates of the neuroprotective effect of the neurotransmitter noradrenaline on dopaminergic neurons. Mol Pharmacol. 2002;62: 1043-1052.
